batch purification using glutathione Simplification of Fed-Batch Processes with a Single-Feed Strategy Glutathione Quantification in Live Cells

Nota bene: HCys and MMA are elevated when renal function declines

Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology

Aging Cell 19 , e13208 (2020)

STORAGE Lyophilized 4 C 24 months, 20 C indefinite Reconstituted 28 C, 28 days PEER-REVIEWED EVIDENCE Sikiric P, Sever M, Krezic I, et al

Other investigations have concluded that viral infections could be the result of mycotoxins exposure and this could be observed when considering the case of porcine circovirus type 2 (PCV2), a small, non-enveloped, single-stranded circular DNA virus

Clinical trials report gastrointestinal adverse events in 25-40% of participants, with severity often declining after 4-8 weeks of continued use